Order Article Reprints

Yamamoto T, Satoi S, Yamaki S, Hashimoto D, Ishida M, Ikeura T, Hirooka S, Matsui Y, Boku S, Nakayama S, et al. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers. 2022; 14(5):1354. https://doi.org/10.3390/cancers14051354

Yamamoto, Tomohisa, Sohei Satoi, So Yamaki, Daisuke Hashimoto, Mitsuaki Ishida, Tsukasa Ikeura, Satoshi Hirooka, Yuki Matsui, Shogen Boku, Shinji Nakayama, and et al. 2022. "Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit" Cancers 14, no. 5: 1354. https://doi.org/10.3390/cancers14051354

Yamamoto, T., Satoi, S., Yamaki, S., Hashimoto, D., Ishida, M., Ikeura, T., Hirooka, S., Matsui, Y., Boku, S., Nakayama, S., Nakamaru, K., Shibata, N., Katsushima, U., & Sekimoto, M. (2022). Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 14(5), 1354. https://doi.org/10.3390/cancers14051354